Pure Global
NCT06360315

Impact of a Letter Encouraging Pneumococcal Vaccination on the 1-year Vaccination Rate in Heart Failure Patients With a Primary Care Physician

University Hospital, Montpellier·ClinicalTrials.gov·otherRecruitment Completed
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Chronic Heart Failure
Drug/Device/Intervention
Incentive letter for pneumococcal vaccination to the patient and to the GP
Study type
Interventional
Intervention type
other
Sponsor & location
Primary sponsor
University Hospital, Montpellier
Location
Montpellier, France
Timeline & enrollment
Phase
N/A
Start date
Jan 02, 2023
End date
Jun 01, 2024
Enrollment
12000 participants
Primary outcome

1-year Pneumococcus vaccination rate

Summary

Heart failure affects more than 1.5 million people in France, resulting in over 70,000 deaths
 and more than 165,000 hospitalizations each year. Viral and bacterial infections are
 frequently associated with episodes of acute heart failure in patients with chronic heart
 failure (CHF). Lower respiratory tract infections, such as influenza and pneumococcus, are
 common causes of hospitalization for decompensated heart failure, leading to increased
 morbidity and mortality. Studies have shown that pneumococcal vaccination can reduce the
 risks of heart attack or stroke in patients with heart failure. However, despite vaccination
 recommendations, coverage rates remain low, especially for pneumococcus. In this study, we
 will evaluate the impact of an incentive letter for pneumococcal vaccination on one-year
 hospitalization rate in patients with heart failure.

ICD-10 classifications
Heart failureHeart failure, unspecifiedCongestive heart failureHypertensive heart disease with (congestive) heart failureHypertensive heart disease without (congestive) heart failure
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06360315
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06360315 through Pure Global AI's free database. This phase not specified trial is sponsored by University Hospital, Montpellier and is currently Recruitment Completed. The study focuses on Chronic Heart Failure. Target enrollment is 12000 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.